Houston researchers are commercializing their organ 3D printing technology. Jordan Miller/Rice University

There may come a time when you or someone you love is in need of a new pair of lungs. Or perhaps it's a liver. It's not a scenario anyone dreams of, but thanks to Houston company Volumetric, you may never end up on a waiting list. Instead, that organ is made to order and 3D printed using a mix of medical plastics and human cells.

And this possibility isn't necessarily in the distant future. On the cover of the May 3 issue of the journal Science, is a contraption that looks a bit like a futuristic beehive. It's a working air sac complete with blood vessels, the beginnings of a technology that is perhaps only a decade from being implanted in humans. And it was crafted on a 3D printer in Jordan Miller's lab at Rice University.

Yes, there are shades of another Houston story — Denton Cooley's implantation of the first artificial heart — but Cooley only inserted the organ. Miller and his bioengineering graduate student Bagrat Grigoryan are primed to profit from their inventions.

In 2018, they started Volumetric Inc., a company that sells both the hydrogel solutions used for printing organs like theirs and the printers themselves. Touring Miller's lab in the Houston Medical Center is a visual timeline of his team's progress designing printers. The version being manufactured is a slick little number, small enough to fit under chemical exhaust hoods, but fitted with everything necessary to print living tissues. It's made and sold in cooperation with CellInk, a larger bioprinting company.

"Our technology is based on projection," Miller explains. Specifically, it's stereolithography, a type of 3D printing that produces the finished product layer-by-layer. Shining colored light of the right intensity turns the polymers into a solid gel.

But why start a company when Miller and Grigoryan are already busy with research?

"If we want to do translational research, commercialization is important," reasons Miller. "We need to build the market to get that technology into the world."

Miller explains that usually the inventor of a technology is the best one to bring it to market.

"When we were building this technology in the lab we saw the potential for commercialization," he recalls. "We do see that this technology is highly scalable. We do think it can have a positive impact on tissue models in a lab."

Those tissue models could one day make not just scientists, but also animal rights activists, very happy. With the technology that Volumetric is developing, scientists could eventually print human cells so well that animal models would be far less accurate in predicting the success that the product being tested would have on humans.

As academics, though, Miller and Grigoryan weren't sure how to start a company. Fortunately, there is the National Science Foundation (NSF) and its I-Corps program. The pair spent a couple of weeks doing a regional program that taught scientists how to commercialize their technology.

"They want to see funded research get out of the lab," Miller says, explaining that they moved on to the national I-Corps program while Miller was on sabbatical from teaching at Rice, allowing them to interview potential customers.

This gave them the confidence to launch last year. Grigoryan now works full-time at the Med Center incubator and accelerator, Johnson & Johnson's JLabs. He has a team of two other scientists on staff.

"It would have been a lot harder to get started if we didn't have a space like JLabs available," Miller says. It also helps, he adds, that JLabs takes no equity, only helping the fledgling brand to finalize its market and get hooked in with potential investors.

Volumetric has its demo units ready to go and expects to start shipping printers in late June, pending final certifications.

"We believe we have technology to make organ replacements for people," Miller says.

And someday soon, long waits for a new set of lungs and a life of antirejection drugs could be a thing of the past.


Rice University bioengineers (from left) Bagrat Grigoryan, Jordan Miller and Daniel Sazer and collaborators created a breakthrough bioprinting technique that could speed development of technology for 3D printing replacement organs and tissues. Photo by Jeff Fitlow/Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.